ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 810

Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity

Heidi Pirttinen1, Kanoktip Puttaraksa1, Robert J. Lagier2, Stanley J. Naides3 and Leona Gilbert1, 1Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland, 2Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, 3Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Apoptosis, autoantibodies, SLE, tolerance and viruses

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  B19 virus (B19V) is common, infects all ages, and is associated with various clinical syndromes including SLE-like autoimmunity. We previously demonstrated that B19 NS1, a superfamily 3 (SF3) viral helicase, is expressed in human cells non-permissive for virion production, damages host cell DNA by single strand nicking and bulky adduct formation, induces apoptosis, and produces apoptotic bodies (ApoBods) that are internalized by phagocytic cells. We hypothesized that ApoBods containing B19 NS1-modified DNA could break tolerance to self DNA. We developed an in vivo mouse model in which mice were inoculated with B19 NS1-induced ApoBods; we then examined serum dsDNA antibody production and tissue damage.

Methods:  A baculovirus expression vector was used to tranduce B19 NS1 in HEp-G2 cells. ApoBods were harvested from culture supernatants at 72 hours post transduction. ApoBods generated by an inducer of apoptosis, staurosporine, were used as a positive control for ApoBods. BALB/c mice were untreated or injected subcutaneously with PBS, or 25 µg, 50 µg or 100 µg, respectively, of B19 NS1-induced ApoBods or staurosporine-induced ApoBods. Pristane, known to induce a lupus-like murine disease, was used as a positive control for autoimmunity induction. Serum dsDNA antibodies were examined with a Crithidia luciliae indirect immunofluorescence assay (IFA) using an anti-mouse IgG conjugate and quantitated with an in-house dsDNA ELISA. Paraffin-embedded tissue sections were examined for immune cell infiltration and damage.

Results:  The Crithidia assay demonstrated positive kinetoplast and nuclear fluorescence staining with sera from mice treated with pristane, staurosporine ApoBods, or B19 NS1 ApoBods. dsDNA antibody by ELISA from 100 µg B19 NS1 ApoBod treated mice was significantly higher than untreated (p<0.0001), PBS-treated (p<0.0001), 100 µg Staurosporine ApoBod-treated (p<0.0006), and pristane-treated mice (p<0.02). Tissue histology revealed immune cell infiltration in kidney, brain, liver, and heart in treated groups, but not in untreated or PBS control groups.

Conclusion:  B19  NS1 ApoBod inoculation induces dsDNA autoantibodies and tissue damage. While B19 NS1 ApoBod-, staurosporine ApoBod-, and pristane-treated mice all had tissue damage and dsDNA antibody by Crithidia testing, the B19 NS1 ApoBod-treated group had significantly elevated dsDNA antibody by ELISA compared to the other groups. This study supports the hypothesis that B19V and possibly other SF3 helicase-expressing viruses, such as Epstein-Barr virus, can induce tissue damage and dsDNA antibody production above that seen with ApoBods alone; dsDNA antibody production may be induced through helicase modification of self DNA.


Disclosure: H. Pirttinen, None; K. Puttaraksa, None; R. J. Lagier, None; S. J. Naides, None; L. Gilbert, None.

To cite this abstract in AMA style:

Pirttinen H, Puttaraksa K, Lagier RJ, Naides SJ, Gilbert L. Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/human-parvovirus-b19-nonstructural-protein-1-ns1-helicase-breaks-tolerance-to-self-dsdna-a-model-for-viral-induction-of-autoimmunity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-parvovirus-b19-nonstructural-protein-1-ns1-helicase-breaks-tolerance-to-self-dsdna-a-model-for-viral-induction-of-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology